BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38226451)

  • 1. Altered tumor signature and T-cell profile after chemotherapy reveal new therapeutic opportunities in high-grade serous ovarian carcinoma.
    Kang H; Hwang S; Kang H; Jo A; Lee JM; Choi JK; An HJ; Lee HO
    Cancer Sci; 2024 Mar; 115(3):989-1000. PubMed ID: 38226451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell sequencing reveals effects of chemotherapy on the immune landscape and TCR/BCR clonal expansion in a relapsed ovarian cancer patient.
    Ren Y; Li R; Feng H; Xie J; Gao L; Chu S; Li Y; Meng F; Ning Y
    Front Immunol; 2022; 13():985187. PubMed ID: 36248860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive transcriptomic and immune infiltrate responses in the tumor immune microenvironment following neoadjuvant chemotherapy in high grade serous ovarian cancer reveal novel prognostic associations and activation of pro-tumorigenic pathways.
    James NE; Woodman M; De La Cruz P; Eurich K; Ozsoy MA; Schorl C; Hanley LC; Ribeiro JR
    Front Immunol; 2022; 13():965331. PubMed ID: 36131935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
    Xu J; Fang Y; Chen K; Li S; Tang S; Ren Y; Cen Y; Fei W; Zhang B; Shen Y; Lu W
    Clin Cancer Res; 2022 Aug; 28(16):3590-3602. PubMed ID: 35675036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
    O'Donnell T; Christie EL; Ahuja A; Buros J; Aksoy BA; Bowtell DDL; Snyder A; Hammerbacher J
    BMC Cancer; 2018 Jan; 18(1):87. PubMed ID: 29357823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune profile of primary and recurrent epithelial ovarian cancer cases indicates immune suppression, a major cause of progression and relapse of ovarian cancer.
    Kumar P; Ranmale S; Mehta S; Tongaonkar H; Patel V; Singh AK; Mania-Pramanik J
    J Ovarian Res; 2023 Jun; 16(1):114. PubMed ID: 37322531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer.
    Kreuzinger C; Geroldinger A; Smeets D; Braicu EI; Sehouli J; Koller J; Wolf A; Darb-Esfahani S; Joehrens K; Vergote I; Vanderstichele A; Boeckx B; Lambrechts D; Gabra H; Wisman GBA; Trillsch F; Heinze G; Horvat R; Polterauer S; Berns E; Theillet C; Cacsire Castillo-Tong D
    Clin Cancer Res; 2017 Dec; 23(24):7621-7632. PubMed ID: 28972047
    [No Abstract]   [Full Text] [Related]  

  • 9. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
    J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer.
    Adzibolosu N; Alvero AB; Ali-Fehmi R; Gogoi R; Corey L; Tedja R; Chehade H; Gogoi V; Morris R; Anderson M; Vitko J; Lam C; Craig DB; Draghici S; Rutherford T; Mor G
    Front Immunol; 2023; 14():1204148. PubMed ID: 37435088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    Silva R; Glennon K; Metoudi M; Moran B; Salta S; Slattery K; Treacy A; Martin T; Shaw J; Doran P; Lynch L; Jeronimo C; Perry AS; Brennan DJ
    Int J Cancer; 2023 Jul; 153(1):120-132. PubMed ID: 36883413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis.
    Yang B; Li X; Zhang W; Fan J; Zhou Y; Li W; Yin J; Yang X; Guo E; Li X; Fu Y; Liu S; Hu D; Qin X; Dou Y; Xiao R; Lu F; Wang Z; Qin T; Wang W; Zhang Q; Li S; Ma D; Mills GB; Chen G; Sun C
    Cell Rep Med; 2022 Dec; 3(12):100856. PubMed ID: 36543113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
    Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
    J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.
    Xu AM; Haro M; Walts AE; Hu Y; John J; Karlan BY; Merchant A; Orsulic S
    Sci Adv; 2024 Apr; 10(16):eadk8805. PubMed ID: 38630822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Cell RNA-Sequencing Atlas Reveals the Tumor Microenvironment of Metastatic High-Grade Serous Ovarian Carcinoma.
    Deng Y; Tan Y; Zhou D; Bai Y; Cao T; Zhong C; Huang W; Ou Y; Guo L; Liu Q; Yin D; Chen L; Luo X; Sun D; Sheng X
    Front Immunol; 2022; 13():923194. PubMed ID: 35935940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Montfort A; Pearce OM; Topping J; Chakravarty P; Everitt GL; Clear A; McDermott JR; Ennis D; Dowe T; Fitzpatrick A; Brockbank EC; Lawrence AC; Jeyarajah A; Faruqi AZ; McNeish IA; Singh N; Lockley M; Balkwill FR
    Clin Cancer Res; 2016 Jun; 22(12):3025-36. PubMed ID: 27306793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.